Analysis on prenatal serological screening results of 23 921 cases with down syndrome.

Objective:To explore the clinical application value of prenatal serological screening for Down syndrome.Methods:The serum levels of alpha-fetoprotein (AFP),free beta-human chorionic gonadotrophin (Free-β-HCG) and unconjugated estriol (uE3) of 23 921 pregnant women with 14～21 gestational weeks were detected by automatic fluoroimmunoassay,chromosome examination of amniotic fluid cells was conducted on positive pregnant women.Results:Among 23 921 pregnant women,1 494 pregnant women were found with high risk factors of Down syndrome,and 1 048 pregnant women received karyotype analysis of amniotic fluid cells.66 pregnant women (6.30%) were found with abnormal karyotypes;11 pregnant women (1.05%) were diagnosed as 21 trisomy syndrome;the abnormal rate of fetus of pregnant women35 years (56/776,7.22%) was higher than that of pregnant women≥35 years (10/272,3.68%)(P=0.04).Conclusion:Prenatal serological screening is an effective method to prevent the birth of infants with chromosome anomaly,and prenatal serological screening combined with other tests may promote screening effects.